Costs of extended immune check point inhibitors treatment in advanced/metastatic lung cancer: Bundling of costs proposal.

被引：0
|
作者：
Guirgis, Helmy M. [1 ]
机构：
[1] Canc Free Fdn, Dana Point, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21738
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Costs of the immune check point inhibitors versus survival ratio in first-line non-small lung cancer, cost bundling proposal.
    Guirgis, Helmy M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Costs and values of the immune check point inhibitors antibodies in non-small cell lung cancer
    Guirgis, Helmy M.
    Langer, Corey J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Limits on costs and values of anticancer drugs in metastatic colorectal cancer: Policies and proposal.
    Guirgis, Helmy M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [4] Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?
    Luke, Jason John
    Ott, Patrick Alexander
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (18) : 2457 - 2462
  • [5] Costs comparison of the immune check point inhibitors versus survival ratio in first-line non-small lung cancer.
    Guirgis, Helmy M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Immune check point inhibitors in BRAF mutated metastatic colorectal cancer: A review
    Colombo, Alfredo
    Cordio, Stefano
    Porretto, Concetta Maria
    INTERNATIONAL JOURNAL OF GASTROINTESTINAL INTERVENTION, 2024, 13 (03): : 74 - 81
  • [7] Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer
    Soares, Adriana
    Carmo, Rafael
    Rodrigues, Catarina
    Grilo, Ines Teles
    Grande, Enrique
    BLADDER CANCER, 2020, 6 (01) : 1 - 8
  • [8] Safety of immune check-point inhibitors in patients with autoimmune conditions and advanced cancer
    Gard, G.
    Van Hagen, T.
    Ariyapperuma, M.
    Feeney, K.
    Roberts-Thomson, R.
    Millward, M.
    Khattak, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer
    Hou, Wanting
    Zhou, Xiaohan
    Yi, Cheng
    Zhu, Hong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] Costs and hazard ratios of commonly used drugs in advanced/metastatic lung cancer at Cancer Free Foundation, Dana Point, California.
    Guirgis, Helmy M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345